CURRICULUM VITAE. Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer.



Similar documents
CURRICULUM VITAE. Key Qualifications: Internal Medicine Specialist and Medical oncologist. Name of Hospital: Firat Universitesi Hastanesi

4-Deveci F, Akbulut HH, Çelik I, Muz MH Ilhan F. Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients, Mediators Inflamm., 2006;(2);89070.

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

CURRICULUM VITAE. Key Qualifications: Gastroenterology, Hepatology, Pancreatobiliary system

Locoregional & advanced esophagus or esophagogastric junction cancer

NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy

Avastin: Glossary of key terms

New strategies in anticancer therapy

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Avastin in breast cancer: Summary of clinical data

Proton Therapy Center Czech

Corporate Medical Policy

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.

Update on Small Cell Lung Cancer

Small Cell Lung Cancer

Avastin in breast cancer: Summary of clinical data

POLICY A. INDICATIONS

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Our Facility. Advanced clinical center with the newest and highly exact technology for treatment of patients with cancer pencil beam

Ching-Yao Yang, Yu-Wen Tien

MEDICAL POLICY POLICY TITLE

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer

Small Cell Lung Cancer

Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

A23: Oncologic Disease- Tumor Markers

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Lung Cancer: More than meets the eye

The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer

10 th EADO Congress Vilnius, 7-10 May Ipilimumab update. Michele Maio

Before, Frank's immune cells could

Pediatric Oncology for Otolaryngologists

False positive PET in lymphoma

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

MICRONUTRIENTS IN CANCER

Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study

SUPERVĐSOR ĐN CHARGE OF TRAINING: Şef Dr Kunter Perim

Role of clinical trials in professional development

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

Emerging Drug List GEFITINIB

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Number. Source: Vital Records, M CDPH

Cancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Survivorship Care Plans Guides for Living After Cancer Treatment

Kidney Cancer OVERVIEW

New Hampshire Childhood Cancer

PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.

What is neuroendocrine cervical cancer?

Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

Cetuximab (Erbitux) MM /10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Current Status and Future Direction of Proton Beam Therapy

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Co-pay assistance organizations offering assistance

Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd

IMMUNOMEDICS, INC. February Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

Trastuzumab (Herceptin ) for patients with metastatic breast cancer

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Characterisation of a Palliative Care Population in a Comprehensive Cancer Centre

What is a Stem Cell Transplantation?

Intravesical Therapy for Bladder Cancer

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

National Cancer Drugs Fund List (Updated 13 February 2014)

E UROPEAN CURRICULUM VITAE FORMAT

Cytotoxic and Biotherapies Credentialing Programme Module 2

CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

Metastatic Breast Cancer: RAOM Clinical Practice Guidelines

Comparing Immunotherapy with High Dose IL-2 and Ipilimumab

THYROID CANCER. I. Introduction

Ovarian Cancer. in Georgia, Georgia Department of Human Resources Division of Public Health

Oncology. Topic-Bile Duct Carcinoma. Topic-Adenocarcinoma, Lung. Topic-Hemangiosarcoma, Spleen and Liver

Gastric or gastroesophageal junction cancer, advanced, as first-line therapy in combination with fluoropyrimidine-based

Prior Authorization Guideline

Small-Cell Lung Cancer: Is There a Standard Therapy?

BOLETIN BIBLIOGRAFICO BIBLIOTECA MEDICA-HCG JUNIO 2014

Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

Report series: General cancer information

Stem Cell Transplantation

Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment

Hospital-Based Tumor Registry. Srinagarind Hospital, Khon Kaen University

Breast Cancer. Breast Cancer Page 1

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015

Yttrium-90 Radioembolization

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France

Crosswalk for Positron Emission Tomography (PET) Imaging Codes G0230 G0030, G0032, G0034, G0036, G0038, G0040, G0042, G0044, G0046

Transcription:

CURRICULUM VITAE Personal Details Surname: KARAOGLU First Name: Aziz Akademic title/ position: Asscociate Proffessor Key Qualifications: -Internal Medicine, -Medical Oncology Research Interest: Bresat Cancer, Gyneocologic Cancer, Colorectal Cancer, Lung Cancer. International Experience/Collaborations: - Contact Details: Work Address: Firat University, Medical School, Medical Oncology Department Name of Hospital: Firat University Hospital Street:... Town: ElAZIG Country: Turkey Post Code:... Phone/Fax: + 90 424 233 35 55 / + 90 424 2388096 Email: azizk6@yahoo.com Date of Birth: 15.09.1966 Place and Country of Birth: IZMIR, TURKEY Country of Citizenship: Republic of Türkiye Country of Training: Türkiye First Language: Turkish Languages: English

Akademic Details Faculty/University ( name and address) Date of Graduation: 1990 Medical School / Firat University Postgraduate Training: ( Name and address of Center and Supervisor [s] in charge of Training) 1-Training of Internal Medicine Firat University Medical School Department of Internal Medicine ELAZIG 2-Training of Medical Oncology Hacettepe University Institute of Oncology Ankara, Turkey SUPERVISOR IN CHARGE OF TRAINING: From To 1-Training of Internal Medicine : 1991-1997 2-Training of Medical Oncology: 1999-2002 Title of thesis: 1. Effectiveness of Intravenous Omeprazole and Ranitidine For Gastrointestinal Bleedings of Acid-Peptic Disease 2. The prognostic significance of cyclin D1, p27, and cyclin E and their correlations wih other prognostic factors in stage III epithelial ovarian carcinoma Accreditation: Government body (Name, number and date of certificate issued by Universty, Medical Association or Government Body) Academic Experience: Associate Professor Memberships: 1-European Society for Medical Oncology 2-Anatolian Society for Medical Oncology (Turkey) 3-Society for Oncology Group (Turkey)

4-Society for Medical Oncology (Turkey) 5-Society for Internal Medicine (Turkey) 6-Society for Firat University Internal Medicine International Publications 1. Karaoglu A, Aydin S, Dagli AF, Cummings DE, Ozercan IH, Canatan H, Ozkan Y. Expression of obestatin and ghrelin in papillary thyroid carcinoma. Mol Cell Biochem. 2008 Nov 28. [Epub ahead of print] 2. Dagli AF, Aydin S, Karaoglu A, Akpolat N, Ozercan IH, Ozercan MRGhrelin expression in normal kidney tissue and renal carcinomas. Pathol Res Pract. 2008 Dec 1. [Epub ahead of print] 3. Topkan E, Polat Y, Karaoglu A. Primary mucinous adenocarcinoma of appendix treated with chemotherapy and radiotherapy: a case report. Tumori, 94, 596-599 (2008). 4. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan O, Unek T, Yilmaz U. Epidemiology and Survival of Hepatocellular Carcinoma in Turkey: Outcome of Multicenter Study. Jpn J Clin Oncol. 2008 Aug 27. 5. Celik H, Gurates B, Karaoğlu A, Yavuz A, Dagli F, Ozercan R. Uterine primitive neuroectodermal tumor: a case report. Arch Gynecol Obstet. 2008 Jun 4. [Epub ahead of print] 6. Topkan E, Karaoglu A. Urine calcium and deoxypyridinoline in assessment of response to local radiation therapy for metastatic bone disease. J Exp Clin Cancer Res. 26(4):553-9 (2007.) 7. Topkan E, Karaoglu A. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. Oncology. 2006;71(5-6):354-60. 8. Aydin S, Geckil H, Karaoglu A, Elkiran ET. Med Hypotheses. 2007;69(5):1157-8. Ghrelin: a novel peptide with therapeutic effect in certain cancers? 9. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer. 15;7:48 (2007) 10. Balci TA, Ciftci I, Karaoglu A. Incidental DTPA and DMSA uptake during renal scanning in unknown bone metastases. Ann Nucl Med. 20(5):365-9, (2006)

11. Elkıran E, Aygen B, Karaoğlu A, Altundag K. Metastatic Osteosarcoma to The Brain in Adult Patient. J Neurooncol. 76(2):213 (2006).. 12. Erma M, Baltalı E., Karaoğlu A, Abali H, Engin H, Ozisik Y, Guler N, Altundag K, Atahan IL, Sayek I, Tekuzman G. A Phase II Study on The Safety and Efficacy Of 5- Fluorouracil, Epirubicin, Cyclophoshpamide (FEC) Followed By Paclitaxel In The Adjuvant Treatment Of Breast Cancer. Cancer Invest 23 (3): 215-21 (2005). 13. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212:116-23 (2005). 14. Nazıroğlu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E adminstration protects cisplatin-induced oxidative damage on renal, liver, and lens tissues in rats, Toxicology, 195, 221-230 (2004). 15. Karaoğlu A, Yalcin S, Tekzuman G, Kars A, Çelik I, Güler N, Özışık Y, Türker A, Barışta Đ, Güllü Đ. Weekly irinotecan in patients with metastatic colorectal cancer failing 5- Fluorouracil-based chemotherapy : Efficacy and Prognostic Factors. Tumori, 89, 141-145 (2003). 16. Karaoğlu A, Altundağ K, Erman M, Engin H, Güllü Đ. Familial asynchronous bilateral primary male breast carcinoma. J Exp. Clin Cancer Res, 21, 143-144 (2002). 17. Erman M, Karaoğlu A, Öksüzoglu B, Aydingöz U, Ayhan A, Güler N. Solitary esophageal metastases of breast cancer after 11 years : a case report. Med Oncol, 19, 171-175 (2002). 18. Engin H, Abalı H, Erman M, Karaoğlu A, Çelik Đ, Güler N. Central nervous system sleeding as a first manifestation of immun thrombocytopenic purpura in hodgkin disease. Haematologia (Budap), 31, 373-375 (2002).

Presentations at International Scientific Meetings: 1. Balcı TA, Ciftci I, Karaoglu A. An Unusual Tumor Of The Renal Pelvis : Primary Mucinous Adenocarcinoma. A Case Report. XXIII. World Congress Of Pathology And Laboratory Medicine. May 26 th -30 th 2005 Istanbul-Turkey. 2- Elkiran T, Celebi S, Aygen B, Karaoglu A, Ozercan I. Primary Malignant Melanoma Of Esophagogastric Junction : A Case Report. XXIII. World Congress Of Pathology And Laboratory Medicine. May 26 th -30 th 2005 Istanbul-Turkey. 3-Aygen B, Elkiran T, Karaoglu A, Akpolat A. An Unusual Tumor Of The Renal Pelvis : Primary Mucinous Adenocarcinoma. A Case Report. XXIII. World Congress Of Pathology And Laboratory Medicine. May 26 th -30 th 2005 Istanbul-Turkey 3- Karaoğlu A, Güler N, Doğan I, Ayhan A, Erman M, Öksüzoğlu B, Çelik Đ, Karaağaoğlu E, Ayhan A. The prognostic significance of cyclin D1, p27, and cyclin E and their correlations wih other prognostic factors in stage III epithelial ovarian carcinoma. 27 th ESMO Congress, 18-22 October, Nice, Annal Oncol, Vol 13, 111, 2002. 4- Karaoğlu A, Yalcin S, Tekuzman G, Erman M, Altundağ O, Oksuzoglu B, Engin H, Altundag K, Guler N. A phase II Study of weekly irinotecan in patients with metastatic colorectal cancer refractory to 5- FU based chemotherapy, American Society of Clinical Oncology, Thirty-Seventh Annual Meeting., May 12-15, 2001-5- Öksüzoglu B, Güler N, Engin H, Karaoğlu A, Baltalı E, Tekzuman G. Intraductal Carcinoma Patients. The Breast Journal, Vol 7, 335-359, 2001, 6-. Karaoğlu A, Yalcin S, Tekuzman G, Erman M, Altundağ O, Oksuzoglu B, Engin H, Altundag K, Guler N. A phase II Study of weekly irinotecan in patients with metastatic colorectal cancer refractory to 5- FU based chemotherapy. American Society of Clinical Oncology, Thirty-Seventh Annual Meeting., May 12-15, 2001. 7. Öksüzoğlu B, Güler N, Engin H, Baltalı E, Karaoğlu A, Altundağ K, Altundağ Ö, Erman E, Özısık Y, Altundağ K. Salvage ifosfamide-etoposide combination after antracycline and taxane failure in advanced breast cancer patents. 11. International Congress on Anti-Cancer Treatment, February 6th to 9th, Paris-France, 2001. 8. Karaoğlu A, Baltali E, Engin H, Erman M, Öksüzoğlu B, Altundağ Ö, Altundağ K, Özısık Y, Güler N, Tekzuman G. Combination of docetaxel, epirubicin, cyclophosphamide chemotherapy in metastatic breast cancer. 11. International Congress on Anti-Cancer Treatment, February 6th to 9th, Paris-France, 2001. 9. Engin H, Üner A, Öksüzoğlu B, Karaoğlu A, Altundağ K, Tekzuman G. Lymphoblastic leukemia/lymphoma in adults. A clinicopathological study of 28 cases treated at the Hacettepe University Oncology Institute. 11. International Congress on Anti-Cancer Treatment. February 6th to 9th, Paris-France, 2001

10. Erman M, Baltali E, Engin H, Karaoğlu A, Özısık Y, Güler N, Altundağ K, Atahan L, Sayek Đ, Tekzuman G. FEC followed by paclitaxel in the adjuvant treatment of high-risk breast cancer: preliminary report. Adjuvant Therapy of Primary Breast cancer, 7th International Conference February 21-24 St Gallen/Switzerland, 2001. 11. Abali H, Karaoğlu A, Tekzuman G, Koc Y, Kansu E. IIVP regimen for salvage therapy in patients with relapsed lymphoma prior to autologous stem cell transplantation. American Society of Hematology, Forty-third Annual Meeting, 07-11 December, Orlanda-Florida, 2001. 12. Baydas G, Dönder E, Erçel E, Karaoğlu A, Yılmaz O, Çelik S. Effects of daily vitamin E supplementation on oxidative status and fatty acid composition in rats with diabetes mellitus induced with streptozotocin. 19 th Conference Of European Comparative Endocrinologists, Nijmegen, 1998.